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Résumé
Le glioblastome (gliome de stade IV d’après l’OMS) est la tumeur cérébrale la plus 
fréquente et la plus maligne. Le prognostic reste pauvre à ce jour. En effet, la survie 
moyenne est évaluée à 15 mois, malgré une prise en charge multidisciplinaire comportant 
chirurgie, chimiothérapie et radiothérapie. Différentes études ont montré une diminution de 
l’expression de Wnt inhibitory factor 1 (WIF1) suite à différents mécanismes de régulation 
au niveau génétique et épigénétique. Une récente étude s’est alors concentré sur le 
chromosome 12 et a identifié le rôle potentiel de WIF1 en tant que de suppresseur de 
tumeur. Une diminution de croissance et l’adoption d’un phénotype de sénescence a pu 
être observé chez des cellules tumorales transfectées exprimant WIF1 de manière 
ectopique. Dans ce projet, nous avons investigué l’impact de la ré-expression de WIF1 
dans des cellules de glioblastomes afin d’observer si l’inhibition de Wnt peut conduire à la 
sénescence. Dans un deuxième temps, nous avons mesuré l’expression de p21 et c-Myc. 
p21 jour un rôle clé dans le déclenchement de la sénescence et est directement inhibé par 
c-Myc, lui-même cible de la voie de signalisation Wnt. Nous avons donc examiné si 
l’action de WIF1 peut faire varier l’expression de ces deux gènes. Finalement, nous avons 
analysé l’expression de différents gènes jouant un rôle dans le mécanisme d’autophagie. 
En effet, il a été reporté que l’autophagie cellulaire jouait un rôle dans l’apparition de la 
sénescence. Nous avons alors investigué ce processus pour mettre en évidence une 
éventuelle association avec le phénotype de sénescence observé dans les lignées 
cellulaire transfectées et ré-exprimant WIF1.
Les clones cellulaires ré-exprimant WIF1 ont été sélectionnés après transfection de 
cellules stables de glioblastome. Les analyses ont été réalisées à l’aide de qPCR 
(quantitative polymerase chain reaction), FACS (fluorescence-activated cell sorting) et 
histochimie. IGFBP7 et ALDH1A3 ont été choisis pour refléter la sénescence. ATG5, 
ATG7 et ULK3 ont été choisis pour refléter l’activité autophagique.
Nous avons observé au sein des lignées ré-exprimant WIF1 un plus grand pourcentage de 
cellules agrandies, multinuclées, comportant une granularité cellulaire augmentées et 
positives à la beta-galactosidase, ce qui correspond aux différentes caractéristiques de la 
sénescence. Une augmentation de l’expression de gènes associés à la sénescence a 
aussi été mise en évidence dans ces mêmes lignées. Toutes ces caractéristiques ont pu 
être corrélées aux différents taux d’expression de WIF1. Nous n’avons pas remarqué 
d’association entre les expressions de WIF1 et de p21, ni entre celles de WIF1 et de c-
Myc. Une correlation entre l’expression des gènes associés au mécanisme d’autophagie 
et de ceux associés à la sénescence a pu être observée dans une des deux lignées 
cellulaire analysées.
Suite à nos investigations à différents niveaux, nous avons l’évidence de l’apparition d’un 
phénotype de sénescence auprès des lignées cellulaire ré-exprimant WIF1. Ce fait permet 
de reconnaître un certain rôle de la voie de signalisation Wnt dans la tumorigénicité du 
glioblastome. Des analyses supplémentaires sont nécessaires pour investiguer par quel 
biais l’inhibition de Wnt conduit à l’apparition de la sénescence. Le rôle de l’autophagie 
dans ces cellules sénescentes reste peu clair. On peut observer des correlations au 
niveau transcriptionnel, laissant en effet penser à une implication de l’autophagie, 
cependant il est encore trop  tôt pour clairement identifier la nature de ces associations. 
Des expériences supplémentaires sont là aussi nécessaires pour confirmer ces résultats 
préliminaires puis analyser la variation d’activité autophagique sur une durée de temps 
définie.
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Abstract
Introduction: Glioblastoma (WHO Grade IV glioma) is the most frequent and most 
malignant primary tumor of the brain. With a mean survival of 15 months despite 
multidisciplinary management combining surgery, chemo- and radiotherapy, the prognosis 
is poor. Different studies measured a down-regulation of Wnt Inhibitory Factor 1 (WIF1) 
expression in a majority  of gliobastoma due to genetic and epigenetic regulation. Recently, 
a focus on chromosome 12 identified WIF1 as a potential tumor suppressor gene. In 
previous results, transfected glioblastoma cells with ectopic expression of WIF1 had a 
decreased growth rate and adopted a senescence-like phenotype. In this report, we first 
investigated the effect of WIF1 re-expression in glioblastoma cell lines to see if Wnt 
inhibition by  WIF1 can lead to senescence. To look further, we assessed p21 and c-Myc 
expression. p21 has a key role in senescence onset and is directly inhibited by c-Myc, 
itself a target of Wnt-pathway. We thus looked if a variation of expression of these genes is 
triggered by WIF1 activity. Finally, as autophagy is thought to play a role in senescence 
onset, we analyzed the expression of different autophagy genes. We therefore looked for 
an association between autophagy activity and senescent phenotype in WIF1-
overexpressing cell lines.
Methods: WIF1-overexpressing clones were selected after transfection of stable 
glioblastoma cell lines. Analysis were made through quantitative Polymerase Chain 
Reaction (qPCR), Fluorescence-activated Cell Sorting (FACS) and histochemistry. 
IGFBP7 and ALDH1A3 have been selected to reflect senescence. ATG5, ATG7 and ULK3 
have been selected to reflect autophagy activity.
Results: Using FACS analysis, we found a higher percentage of large cells with increased 
granularity  amongst WIF1-overexpressing cell lines, which are characteristics of 
senescence. In addition, histochemistry showed a higher percentage of multi-nucleated, 
beta-galactosidase positive cells in the same cell lines. An increased expression of genes 
associated with senescence was found as well. All characteristics were correlated with 
levels of WIF1 expression. We did not find any association between p21 and WIF1 
expression. No correlation between WIF1 and c-Myc expression was noticed either. In one 
of the two cell lines analyzed, the expression of autophagy genes showed some 
correlation with expression of WIF1 and  expression of genes associated with senescence.
Discussion: After investigations and characterizations on multiple levels, we have 
evidence for a senescence phenotype upon WIF1-overexpressing cell lines. This gives a 
role to Wnt pathway in the tumorigenicity  of glioblastoma. Further experiments are 
required to investigate how Wnt inhibition leads to senescence. The role of autophagy in 
our senescent cells is here still unclear. Some correlations can be found, letting us think 
that there is indeed some involvement of autophagy. However, it is yet to soon to explain 
this relationship. Further experiments are required again to confirm the preliminary results 
and analyze the variations of autophagy activity within time.
Keywords: glioblastoma, WIF1, senescence, autophagy, Wnt pathway
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Introduction
With an incidence of 2.6 new cases for 100’000 habitants, representing 30% of cerebral 
tumors, Glioblastoma (WHO Grade IV Astrocytoma) is the most frequent and most 
malignant primary  tumor of the brain.1  Radiation and genetic predisposition are currently 
the only known causes. Two distinct presentations have been identified: primary 
glioblastomas occur de novo and represent up to 90% of glioblastomas while secondary 
glioblastomas develop  from a lower grade glioma and represent the remaining 10%. Both 
patterns exhibit defined pathology with specific characteristics. Epidermal Growth Factor 
Receptor (EGFR) amplification (36% of cases) and loss of heterozygosity 10q (47% of 
cases) are two typical modifications found in primary glioblastomas whereas in secondary 
glioblastomas, IDH1 and p53 mutations are the most frequent genetic alterations (85% 
and 65% of cases respectively).2  These alterations can already be found in a majority of 
precursor low-grade astrocytomas [Fig.1]. 
Fig. 1. Genetic pathways to astrocytic and oligodendroglial diffuse gliomas. LOH, loss of heterozygosity.2
Interestingly, EGFR amplification and p53 mutation are mutually exclusive, separating 
primary and secondary glioblastomas in two well-distinguished entities. Moreover, there is 
also a difference in the age distribution. The mean age for primary glioblastoma is 62 
secondary glioblastomas, but not primary glioblastomas,
share common IDH1/2 mutations with oligodendroglio-
mas; (2) primary and secondary glioblastomas develop in
patients of different age groups; and (3) these glioblastoma
subtypes have significantly different biological behavior.
If this is the case, cancer stem cells in primary and
secondary glioblastomas may also be different. One study
showed that the relative content of CD133? cells was
significantly higher in primary than in secondary glio-
blastomas, and that CD133? expression was associated
with neurosphere formation only in primary but not in
secondary glioblastomas [27]. Lottaz et al. [28] compared
gene expression profiles in 17 glioblastoma cancer stem
cell (CSC) lines and in their different putative founder
cells. Two subgroups of glioblastoma were distinguished:
type I CSC lines displaying ‘‘proneural’’ signature genes
and resembling fetal neural stem cell (NSC) lines, and type
II CSC lines showing ‘‘mesenchymal’’ transcriptional
profiles and resembling adult NSC lines [28]. Since glio-
blastomas with IDH1 mutations typically have a proneural
signature [23], secondary glioblastomas may derive from
cells that have preserved or acquired the properties of fetal
NSC lines, distinct from those of adult NSC lines [28].
Another possibility would be that primary and second-
ary glioblastomas develop from the same precursor cells,
but show distinct biological behavior because of different
genetic alterations, most importantly, the absence or pres-
ence of IDH1/2 mutations. If this is the case, specific glial
progenitor cells present in younger patients could be mor
susceptible to the acquisition of IDH1/2 mutations and the
consequent growth advantage than those cells present in
older patients.
Genetic pathways to primary and secondary
glioblastoma
Our current concept of genetic pathways to astrocytic and
oligodendroglial diffuse gliomas is summarized in Fig. 4.
Diffuse astrocytomas and oligodendrogliomas may origi-
nate from common glial precursor cells carrying IDH1/2
mutations. The additional loss of 1p/19q in cells with
IDH1/2 mutations may favor the acquisition of the oligo-
dendroglial phenotype. Secondary glioblastomas share a
common cellular origin with oligodendrogliomas, whereas
primary glioblastomas may derive from different precursor
cells lacking IDH1/2 mutations (Fig. 4). The common
Table 2 Genetic alterations
that are prognostic for
glioblastoma patients
at the population level
(multivariate analysis)
* Significantly associated with
longer survival
** Significantly associated with
shorter survival
Genetic alteration No. of cases Hazard ratio
(95% CI)
References
IDH1 mutation 203 0.29 (0.16–0.51)* Nobusawa et al. [17]
TP53 mutation 386 0.86 (0.69–1.07) Ohgaki et al. [11]
PTEN mutation 324 0.99 (0.76–1.28) Ohgaki et al. [11]
p16INK4a deletion 328 0.90 (0.71–1.14) Ohgaki et al. [11]
EGFR amplification 371 1.08 (0.87–1.34) Ohgaki et al. [11]
1p36 loss 231 0.7 (0.5–1.0)* Homma et al. [14]
19q13 loss 218 0.7 (0.4–1.2) Homma et al. [14]
LOH 10q 269 1.28 (0.98–1.67)** Ohgaki et al. [11]
Glial progenitor cells
Common precursor cells
Loss 1p/19q (>75%)
Anaplastic 
oligodendroglioma
Diffuse astrocytoma
Anaplastic 
astrocytoma
Secondary
Glioblastoma
TP53 mutation (>65%)
LOH 10q (>60%)
Primary
glioblastoma
Glial progenitor cells
EGFR amplification (~35%)
TP53 mutation (~30%)
PTEN mutation (~25%)
NF1 alteration (~20%)
LOH 10p (~70%)
LOH 10q (~70%)
Oligodendroglioma
IDH1 mutation (>85%)
II
III
IV
Fig. 4 Genetic pathways to
astrocytic and oligodendroglial
diffuse gliomas.
LOH, loss of heterozygosity
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years, whereas secondary glioblastoma presents earlier, with a mean age of 45 years. 
These properties define two distinct pathologies, each with different evolutions, as well as 
different clinical profile.3
The current standard protocol of care is multidisciplinary, including surgical resection, 
radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide. Despite 
constant improvements, the prognosis remains poor. The actual mean survival is 15 
months.4,5 There is thus a pressing need of new targets to control this deadly disease.
Lambiv et al. investigated the 12q13 and 12q15 chromosomal regions containing MDM2 
and CDK4.6  A gene expression-based prediction of copy number aberrations has been 
performed [Fig. 2] and showed a significantly lower expression of Wnt Inhibitory Factor 1 
(WIF1) in glioblastoma in comparison with non-neoplastic brain tissues. This lends WIF1 a 
potential tumor suppressor role.
Fig. 2. Gene expression–based prediction of copy number aberrations (CNAs) in glioblastoma. (A) The 
maximum (red) and mean (blue) amplification probabilities on chromosome 12q14–12q15 were estimated 
from glioblastoma gene expression data by a hidden Markov model (HMM). The interrogated region flanked 
by CDK4 and MDM2 encompasses a ~11 Mb window.6
Wnt signaling plays an important role in embryonic development but is also known for 
having a strong association with oncogenesis.7  Wnt takes part in two different pathways. 
The canonical one is ß-catenin dependent [Fig. 3]. When no ligand activates Frizzled, the 
receptor, ß-catenin is sequestered in the cytoplasm and led to proteolysis by  a complex 
including APC, AXIN and GSK-3ß. The activation of the receptor by  Wnt ligand leads to 
inhibition of this complex, allowing ß-catenin to translocate into the nucleus and induce 
transcription. 
in glioblastoma.15,36 The MGMT methylation status
was available for 107 cases from previous studies, of
which 56 were MGMT methylated (52%).5,37–40 Most
established glioblastoma cell lines (14 of 15) showed
hypermethylation of the WIF1 promoter. Only LN992
exhibited an unmethylated WIF1 promoter. Treatment
Fig. 1. Gene expression–based prediction of copy number aberrations (CNAs) in glioblastoma. (A) The maximum (red) and mean (blue)
amplification probabilities on chromosome 12q14–12q15 were estimated from glioblastoma gene expression data by a hidden Markov
model (HMM). The interrogated region flanked by CDK4 and MDM2 encompasses a !11 Mb window. (B) The respective mean DNA
copy number of this chromosomal region was determined by array comparative genomic hybridization (aCGH, Humarray 3.0 and 3.1 of
the University of California at San Francisco; manuscript in preparation). The bacterial artificial chromosome (BAC) probes are ordered by
their genomic positions. The BACs corresponding to CDK4 and MDM2 BACs are shown in red. (C) The heat map visualizes the structure
of the aCGH data shown in (B) for the genomic region encompassing 12q13 to 12q15 from 68 glioblastomas. The BACs are ordered by
their genomic position, while the glioblastomas on the x-axis are ordered by similarity using Sorting Points into Neighborhood
software.57 Blue depicts deletion; red, amplification; and white, missing data. The color scale is truncated to [21, 1] for presentation.
The BAC corresponding to CDK4 is GS-561N1; for MDM2, CTB-136O14 (red); and for WIF1, RP11-18B8 (blue). (D) WIF1 expression
(Affymetrix probe set 204712_at) in glioblastoma is significantly lower than in nonneoplastic brain tissues (P ¼ .001), as determined in
our gene expression data set.5 (E) Low WIF1 expression was confirmed in 5 independent glioblastoma data sets (Freije et al., red; Rich
et al., violet; Phillips et al., orange; Sun et al., dark blue; Horvath et al., green; our data set, Murat et al., light blue).26–30 WIF1
expression values are median centered within each data set independently.
Lambiv et al.: WIF1 tumor suppressor in glioblastoma
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Fig. 3. (a) When no ligand binds the receptor (Fz), ß-catenin is complexed by APC, AXIN and GSK-3ß and 
thus sequestered and destroyed in the cytoplasm. (b) once Wnt ligands binds Fz, AXIN and GSK3ß are 
recruited, the complex is inhibited, allowing ß-catenin to translocate in the nucleus and induce transcription.8
The non-canonical pathway is ß-catenin independent and works through other 
components. WIF1 mechanism of action includes binding of Wnt ligand, therefore 
preventing its activation of the canonical Wnt signaling. Genetic and epigenetic regulation 
of WIF1 such as promoter hypermethylation, deletion or histone acetylation, were found in 
a majority  of gliobastomas9, 10 , 11  and put in association with a down-regulation of WIF1 
expression. This supports the candidature of WIF1 as a tumor suppressor gene. WIF1 
over-expressing cells were later obtained by transfecting WIF1 into LN319 glioblastoma 
cells [Fig. 4]. Investigations showed a loss of Wnt pathway activity, along with a decreased 
growth rate. At confluence, the cells adopt a large, flat morphology6 referring to what we 
know to be senescence phenotype.
5
In this report, we used polymerase chain reaction (PCR), histochemistry  and fluorescence-
activated cell sorting (FACS) to investigate the effect of WIF1 re-expression in 
glioblastoma cell lines. The aim was to test the ability of WIF1 to lead to senescence by 
inhibiting Wnt signaling.  
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Fig. 4. LN319 cell clones stably transfected with WIF1 show reduced Wnt pathway signaling. Two stably 
transfected LN319 clones were analyzed for WIF1 expression by qRT-PCR (normalized to the control cells 
transfected with the empty vector, pcDNA3.1) (A) and WIF1 secretion by enzyme-linked immunosorbent 
assay (ELISA) (B). Wnt pathway signaling was measured both with the TCF luciferase reporter (TOP5/
FOP5) and normalized to the control cells (C) and by measuring AXIN2 mRNA expression (D). The 
specificity of the WIF1-induced effects in the 2 clones was controlled by transfection of specific siRNAs 
against WIF1 or a respective scrambled control. Wnt pathway signaling was measured using the TCF 
reporter (E) and WIF1 secretion using ELISA (F). Results are marked with 1 asterisk (*) if P,.05 and 2 (**) if 
P,.01.6
In order to further understand how Wnt inhibition leads to senescence, we assessed 
expression of p21 and c-Myc. p21 plays a key role in the control of cell cycle as well as in 
the onset of senescence. It is however down-regulated by c-Myc,12  a direct target of Wnt 
6
signaling. The goal was to see if there is a decreased, respectively increase in c-Myc and 
p21 expression after inhibition of Wnt by WIF1.
Additionally, in order to investigate the onset of senescence in WIF1-overexpressing cells, 
we focused on another cellular process: autophagy. Autophagy  is a genetically regulated 
mechanism characterized by the formation of double-layered cytosolic vesicles, so-called 
autophagosomes, and responsible for an increased turnover of cellular components. 
Autophagy is regulated by mTOR, which inhibits autophagy  induction. In case of nutrient 
depletion or oncogenic stress, mTOR is inhibited, allowing early autophagy genes like 
ULK3 (homolog to ATG1) to start the process13 [Fig. 5]. Although autophagy onset requires 
a large group of genes, ATG5 and ATG7 however were reported to be essential for 
autophagy to be efficient.14 This program is thought to play a crucial role for cell survival, 
especially  when fast metabolic changes occur. It is for example the case in early  neonatal 
period but it can be due to any other metabolic stress. It also assures a certain quality 
control of cellular components and would improve the immune response to pathogens.15
Fig. 5. When activated, mTOR inhibits autophagy. In case of nutrient depletion, genotoxic- or oncogenic 
stress, mTOR is inhibited, allowing early autophagy genes to start the process. ATG5 and ATG7 take place 
later in the cascade and are referred as essential for the effectiveness of the process.16
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However, beside its pro-survival function, autophagy was also shown to have some 
association with cell death on one hand and senescence on the other.17  The correlation 
between autophagy and apoptosis is not completely understood yet due to common 
regulating factors and common components.15 Nevertheless, Young & Narita recently 
reported autophagy as a transition before entering a state of oncogene-induced 
senescence.18  In human diploid fibroblasts (HDFs), an oncogenic stress triggers 
transiently  mTor activation. Later, mTor activity  decreases, allowing autophagy  to become 
activated and the cells undergo senescence [Fig 6].
(Figure 1). Consistent with its survival role, it has been
suggested that autophagy can be a switch between apop-
tosis and senescence [5!]. For example, advanced glycation
end products (AGEs), which are non-enzymatically gener-
ated glycosylatedproteins, cause cytotoxic effects on endo-
thelial cells and AGE-exposed human umbilical vein
endothelial cells (HUVECs) are an in vitro model of
diabetic vasculopathy. The primary response of HUVECs
to AGEs in culture is apoptosis, while the surviving cells
become senescent. In this context, autophagy is transiently
activated following apoptosis. Pharmacological inhibition
of autophagy increases apoptotic cell death with a corre-
sponding attenuation of the senescence response. Thus
autophagy might contribute in part as a survival factor to
shift cell fate from apoptosis [5!].
A more direct link between senescence and autophagy
was recently shown in replicative senescence of HDFs
[4!!]. The members of the BAG (Bcl-2-associated atha-
nogene) protein family can bind to chaperones of the Hsc/
HSP70 family and thereby modulate protein quality
control. Gamerdinger et al. [4!!] found that BAG1 and
BAG3 regulate the proteasomal and autophagic pathways,
respectively, and that the BAG3/BAG1 ratio is elevated
during replicative senescence (Figure 1). BAG3 mediates
the activation of autophagy during replicative senescence
through association with p62/SQSTM1, which binds both
polyubiquitin and LC3 (the mammalian homologue of
atg8). Thus, regulation of polyubiquitinated protein
degradation shifts from the proteasome to autophagy
during replicative senescence. The data suggest that
autophagymight be important in the turnover of damaged
proteins that cannot be processed by the proteasome
during this process. However, whether BAG3 and
BAG3-mediated autophagy contributed to the senes-
cence phenotype has not been addressed.
Autophagy as an effector mechanism of
senescence
Does autophagy actively contribute to the process of
senescence, rather than just cleaning up metabolic waste?
Senescence is a progressive phenotype, but the process
Autophagy and senescence Young and Narita 235
Figure 1
Postulated function of autophagy during senescence establishment. Top: during replicative senescence, the ratio of BAG3 to BAG1 co-chaperone
proteins is elevated. BAG3 and BAG1 regulate autophagy and the proteasome, respectively. Accordingly, the main mechanism of polyubiquitinated
protein degradation shifts from the proteasome to autophagy, the latter being able to handle more severely damaged protein aggregates [4]. Middle:
advanced glycation end products (AGEs), the irreversible products of non-enzymatic glycation of proteins and other macromolecules, are increased in
situations of hyperglycemia and oxidative stress. AGEs are implicated in age-related diseases, such as vascular inflammation in diabetic patients.
Human umbilical vein endothelial cells (HUVECs) in culture undergo apoptosis when exposed to AGEs [5]. Apoptosis is followed by the transient
activation of autophagy and the surviving cells become senescence. Pharmacological inhibition of autophagy enhances apoptosis and consequently
decreases the number of senescent cells. Bottom: upon constitutive activation of ras, human diploid fibroblasts (HDFs) undergo oncogene-induced
senescence (OIS) after the transient activation mTOR, a negative regulator of autophagy [3]. Consistently, autophagy becomes activated upon the
downregulation of mTOR activity. During this process, cells exhibit drastic morphological changes and produce a large amount of secretory proteins.
Apparently, the global rate of protein synthesis is also elevated, thus highly efficient protein turnover might facilitate the acute switch in phenotype
during OIS. (Note that the time scale of each condition is not proportional.)
www.sciencedirect.com Current Opinion in Cell Biology 2010, 22:234–240
Fig. 6. Upon constitutive activation of ras, human diploid fibroblasts (HDFs) undergo oncogene-induced 
senescence (OIS) after the transient activation mTOR, a negative regulator of autophagy. Consistently, 
autophagy becomes activated upon the down-regulation of mTOR activity. During this process, cells exhibit 
drastic morphological changes and produce a large amount of secretory proteins. Apparently, the global rate 
of protein synthesis is also elevated, thus highly efficient protein turnover might facilitate the acute switch in 
phenotype during OIS. (N te that the time scale of each condition is not proportional.)18
W  investigated th  transition of WIF1-overexpressing cell lines into a sen scence-like 
phenotype using ATG5, ATG7 and ULK3 expression to reflect autophagy activity. As 
markers for senescence, two genes were assessed: IGFBP7, part of the IGF pathway and 
ALDH1A3, part of the IFN pathway. Both pathways are known to regulate senescence.19 
This transition was found in non-cancerous cells but not yet in glioblastoma cells. It could 
be therefore relevant to understand what role WIF1 has in senescence onset.
Methods and materials
Glioblastoma cell lines
Glioblastoma cell lines LN229 and LN319 were established in the Laboratory of Brain 
Tumor Biology and G netics, Neuros rgery, Lausanne University Hospital. All glioma cell 
line  have been characterized for a defined set of molecular aberrations20 and were con- 
8
trolled by DNA fingerprinting as described.21  Both cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (Invitrogen), supplemented with 5% fetal calf serum (Hyclone) 
and 100 units/mL penicillin, 100 units/mL streptomycin (Invitrogen). WIF1 was subcloned 
into the vector pIRES2-EGFP and used to transfect LN229. LN319 was stably transfected 
with the WIF1 expression vector and its empty  control pcDNA3.1, generous gifts from 
Professor Qian Tao, Cancer Center, Chinese University  of Hong Kong.22  LN229_C1C, 
LN229_C3A, LN229_C4B, LN229_C4D, LN319-WIF1_C2 and LN319-WIF_C6 were 
selected for their ectopic expression of WIF1. All clones were cultured in the same medium 
as above, supplemented with 8µm/ml of geneticin.
LiCl treatment
2 x 104 cells were seeded onto 12-well plates and let at 37°C for 24h. Using a stock of 3M 
LiCl diluted in PBS, cells were then treated with a concentration of 30mM LiCl for 72h in 
previously described medium.
RNA Isolation and Reverse Transcription PCR
Total RNA was extracted using the RNeasy  total RNA extraction kit (Qiagen), and cDNA 
was synthesized using Superscript RT II (Invitrogen). Real-time quantitative PCR was 
performed with Fast SybR Green Master Mix (Applied Biosystem) using the Rotor Gene 
6000 Real-Time PCR system(Corbett Life Science). PCR reactions were run as 
duplicates. The temperature profile was as follows: 95°C (100 s) followed by 40 cycles at 
95°C (3 s) to 60°C (20 s). The quality  of the products was controlled by the melting curve. 
Transcript levels were normalized against human GAPDH.23
AXIN2 primers.24  P21 primers: Forward: TGGACCTGTCACTGTCTTGT; Reverse: 
TCCTGTGGGCGGATTAG. c-Myc primers: Forward: GAGGCTATCTGCCCATTTG; 
R e v e r s e : A G G C T G C T G G T T T T C C A C T A . p 2 7 p r i m e r s : F o r w a r d : 
AGATGTCAAACGTGCGAGTG; Reverse: TCTCTGCAGTGCTTCTCCAA. The primers for 
ULK3, ATG5 and ATG7 were already described13, just as IGFBP7 and ALDH1A3 primers.25
Flow Cytometry Measurement of Cell Morphology
Cells were grown unti l confluence detached using a solution of 2 mM 
ethylenediaminetetraacetic acid (EDTA) in PBS and resuspended in PBS. Cell size was 
evaluated by forward scatter (FS) and side scatter (SS) analysis using a Beckman Coulter 
9
FC500 5-color analyzer. More than 1 × 104 events were counted for all samples. 
Thresholds for FS and SS were arbitrarily defined.
Histochemistry
Cells were seeded onto glass coverslips coated with poly-L-lysine and cultured until 
confluence. Cells were stained for the activity of SA-b-galactosidase using the b-
Galactosidase Staining Kit (Biovision), following the manufacturer’s instructions, and 
counterstained with 4′ ,6-diamidino-2-phenylindole (DAPI). SA-b-galactosidase activity  and 
nuclear morphology  were visualized by bright field and fluorescence microscopy (Leica 
Leitz DMRB). Cells were scored in 10 randomly taken fields.
Results
LiCl treatment reverses WIF1 inhibition
To test the effect of WIF1 on the Wnt-pathway, we modulated the activity of the pathway 
with Lithium-Chloride (LiCl). LiCl was shown to inhibit GSK-3ß, therefore to activate Wnt 
signaling.26,27 After 72h treatment with 30mM LiCl, we measured AXIN2 expression. AXIN2 
is known to be a direct target of the Wnt-pathway28 and can reflect Wnt activity within the 
cell. We could observe an increased AXIN2 expression amongst all clones after treatment 
[Fig. 7]. The difference between treated cells and non-treated cells was more significant in 
LN319_pcDNA which doesn’t express WIF1.
Fig. 7. Three clones have been treated with LiCl 30mM for 72 hours. mRNA has been analyzed with qPCR. 
All samples were normalized to LN319_pcDNA control. We could see AXIN2 levels increase after treatment. 
The biggest difference  was seen in LN319_pcDNA, the only clone that doesn’t express WIF1.
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WIF1 over-expressing cells adopt a senescence phenotype.
Cell lines with ectopic expression of WIF1 previously showed a striking change in 
morphology once at confluence.6 In addition to decreased growth rates, LN319-WIF1_C2 
and LN319-WIF1_C6 showed enlarged size and flattened shape. We investigated 
recognized characteristics of senescence such as changes of ploidy, SA-ß-galactosidase 
activity  and increased granularity.29  As quantitative analysis, a fluorescent-activated cell 
sorting analysis (FACS) was performed. In FACS analysis, side scatter (SS) and forward 
scatter (FS) are used to identify cells. SS defines the cell granularity, FS defines the size. 
Senescent-like cell specifications were defined as: high granularity, high SS; big cell, high 
FS. A higher percentage of cells with such characteristics was found amongst WIF1-
overexpressing clones in comparison with the control. In addition, this increased 
percentage was proportionally correlated with the respective expression of WIF1 of the 
different clones. The same observation was made after double staining of cells for SA-ß-
galactosidase and DAPI, a DNA specific probe that stains the nucleus.30  Higher 
populations of SA-ß-galactosidase positive and multi-nucleated cells were scored amongst 
both LN319- and LN229-derived WIF1-overexpressing clones [Fig 8].
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Fig. 8. WIF1 expression and detection of senescence-like cells. Cell morphology of the different LN319 
clones was analyzed by fluorescence-activated cell sorting (FACS) (A). Senescence-like cells were defined 
as highly granulated cells, high side scatter (SS) (blue rectangle), and big cells, high forward scatter (FS) 
(red rectangle). (B) Quantification of FACS analysis, % of highly granulated cells (SS high, blue), and % of 
both highly granulated and big cells (FS and SS high, red). Quantification of LN319 (C) and LN229 (E) cells 
positive for SA-b-galactosidase activity scored in 10 different randomly chosen fields. (D, F) Representative 
images of clones stained for SA-b-galactosidase and DAPI are shown (200×). Large, SA-b-galactosidase 
positive (blue) and multi-nucleated cells are highlighted with red arrows. Results are marked with 1 asterisk 
(*) if P , .05 and 2 (**) if P , .01.6
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p21 seems not to play a role in WIF1-induced senescence-phenotype.
LN319_pcDNA, LN319-WIF1_C2 and LN319-WIF1_C6 were tested for p21 and c-Myc 
expression. WIF1-overexpressing cells are sensitive to contact inhibition. All three clones 
were then taken in non-confluent state, defined as 60% of confluence, and confluent stage 
in order to distinguish between a fast- and slow-growing state. All data were analyzed 
using quantitative PCR and are thus reflecting the transcriptional regulation only. 
Although p21 levels appeared to be higher in WIF1-overexpressing cell lines at the non-
confluent stage, it is not the case at a confluent stage. In contrary, p21 levels are higher in 
the control than in both WIF1-overexpressing cell lines [Fig. 9A]. c-Myc levels are similar in 
all three clones at non-confluent stage. At confluent stage however, there is an increased 
c-Myc expression in the control but a decreased expression in the clones expressing WIF1 
[Fig 9B].
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Fig. 9. The RNA of three clones was collected and analyzed with qPCR for p21 and c-Myc expression. All 
samples were normalized to LN319_pcDNA at confluent stage. (A) p21 levels of transcription appeared 
slightly higher in WIF1-overexpressing cells at a non-confluent stage. However it was the other way around 
at confluence. We think that other process are involved at this stage, more likely due to contact inhibition. (B) 
c-Myc levels are similar at non-confluent stage. At confluence however, the expression appeared to drop  in 
WIF1-overexpressing cells. This could be explain by a higher concentration of WIF1 at confluent stage. 
However c-Myc and p21 expressions weren’t correlated.
Autophagy
Amongst LN319 clones, IGFBP7 and especially ALDH1A3 were higher in the cells 
expressing WIF1, with a positive relationship to its level of expression [Fig. 10A]. We can 
observe some similarities to the quantitative analysis previously  shown [Fig. 8A]. 
Expression of autophagy genes, on the other hand, was lower in those cells, exception 
made for ULK3 which was similar in all cell lines [Fig. 10B]. We found no indication of 
increased autophagy in WIF1-overexpressing cells. No clear relationship with WIF1 
expression could be observed at this point.
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Fig. 10. LN319 clones mRNA was analyzed through qPCR for senescence and autophagy genes. (A) There 
was a increased expression of IGFBP7 and especially ALDH1A3 in WIF-overexpressing cell lines. We could 
observe a dose-dependent effect along with WIF1 expression (c.f. Fig 1). (B) ATG5 and ATG7 expression 
appeared lower in WIF1-overexpressing cell lines. ULK3 expression however stayed similar in all three cell 
lines. The relationship to WIF1 expression remains unclear at this point.
Amongst LN229 clones, IGFBP7 expression was higher in WIF1-overexpressing cells, with 
a strong relationship  with WIF1 expression, as it can be observed in LN229-WIF1_C3A 
and LN229-WIF1_C4D, both clones with the highest WIF1 expression. ALDH1A3 
expression showed a similar pattern, with higher expression in LN229-WIF1_C3A and 
LN229-WIF1_C4D but not in the other WIF1-expressing clones. In contrary, the expression 
appeared lower in these cells than in the control [Fig. 11A]. Interestingly, ATG5 and ATG7 
expressions exerted the same pattern as IGFBP7 and ALDH1A3. They show strong 
expression in LN229-WIF1_C3A and LN229-WIF1_C4D which can be correlated to WIF1 
expression [Fig. 11B]. ULK3 expression, however, correlated neither with WIF1 expression 
nor IGFBP7 or ALDH1A3 expression .
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Fig. 11. LN229 clones mRNA was analyzed through qPCR for senescence and autophagy genes. (A) There 
is a strong increase in IGFBP7 expression in WIF-overexpressing cell lines. ALDH1A3 expression on the 
other hand didn’t correlate with WIF1 expression in all clones. Nevertheless, the clones with the highest 
WIF1 expression, LN229_WIF1_C3A and LN229_WIF1_C4D showed an increased ALDH1A3 expression as 
expected (B) Interestingly, ATG5 and ATG7 expression showed a pattern similar to IGFBP7 and ALDH1A3. 
We observed a strong expression in LN229_WFI1_C3A and _C4D which matches WIF1 expression amongst 
these cell lines. ULK3 expression however could not be correlated to any other gene in those results.
Discussion
By investigating specific markers and morphological characteristics, we have evidence for 
a senescence-like phenotype amongst WIF1-overexpressing cells. Moreover, we have 
established that this effect is due to WIF1 activity  as it can be reversed using a Wnt-
pathway activator like LiCl. These last results however can be criticized. The experiment 
has been performed only once. In addition, it does not explain why AXIN2 levels are higher 
in LN319_WIF1_C6 before treatment. In this cell line, Wnt signaling should be inhibited by 
WIF1, keeping AXIN2 expression at a lower level.
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Nonetheless, our data confirms a certain role of Wnt-pathway in the tumorigenicity  of 
glioblastoma, warranting further research in this particular signaling pathway. Moreover, it 
may also offer a target for new treatment strategies.
However, the intracellular process that leads to this state remains however unknown. p21 
and c-Myc are key players in many neoplasiae, although no evidence of association 
between the expression of these genes and WIF1 expression could be found in our case. 
In order to be more certain of these results, our experiments should be repeated at least 
twice. The significantly increased expression of IGFBP7 and ALDH1A3 in LN319- and 
LN229-derived WIF1-overexpressing clones offers new tracks to explain the effect of WIF1 
expression on the onset of senescence. 
At this point, the role of autophagy in this process remains unclear. Autophagy related 
gene expression varies between the onsets of stress and senescence, as shown in human 
fibroblast.13 It is possible that we missed the transition in our samples. We indeed did not 
analyze our samples at different time points. It is however interesting how similar ATG5 
and ATG7 expressions are to ALDH1A3 and IGFBP7 in LN229-related WIF1-
overexpressing cell lines.  This  can be a beginning in understanding the relationship 
between autophagy and senescence. 
Further experiments are clearly  required in order to firstly confirm these results and 
secondly investigate the potential association between the two processes. Does 
autophagy really  mediate the onset of senescence, do they have a common trigger or is it 
just two patterns of the same process? The role of Wnt in autophagy activity stands as a 
challenge as well. Although a down-regulation of Wnt by autophagy itself has been 
described,31  trigger of autophagy by Wnt inhibition has not been shown yet. A way to 
answer these questions is to create a WIF1 inducible system in GBM cell lines. By being 
able to control WIF1 expression in time, we would have the tool to investigate direct 
changes of expression at different time points. We would therefore be able to observe the 
transition into a senescent state, along with levels of autophagy activity. This system is 
currently being developed in the lab.
Glioblastoma is and remains a deadly disease, despite constant improvements in tumor 
management and the better resources we constantly develop  to control it. It is therefore 
essential to further our knowledge and understanding of this devastating tumor in order to 
improve its poor prognosis. The new processes described above can potentially be a step 
17
closer to a better prognosis, highlighting the importance of further observations and 
investigations in them.
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in glioblastoma and has a tumor suppressing
function potentially by induction of
senescence
Wanyu L. Lambiv†, Irene Vassallo†, Mauro Delorenzi, Tal Shay, Annie-Claire Diserens,
Anjan Misra, Burt Feuerstein, Anastasia Murat, Eugenia Migliavacca,
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Gene expression—based prediction of genomic copy
number aberrations in the chromosomal region 12q13
to 12q15 that is flanked byMDM2 and CDK4 identified
Wnt inhibitory factor 1 (WIF1) as a candidate tumor
suppressor gene in glioblastoma. WIF1 encodes a
secreted Wnt antagonist and was strongly downregu-
lated in most glioblastomas as compared with normal
brain, implying deregulation of Wnt signaling, which is
associated with cancer. WIF1 silencing was mediated
by deletion (7/69, 10%) or epigenetic silencing by pro-
moter hypermethylation (29/110, 26%). Co-amplifica-
tion of MDM2 and CDK4 that is present in 10% of
glioblastomas was associated in most cases with deletion
of the whole genomic region enclosed, including the
WIF1 locus. This interesting pathogenetic constellation
targets the RB and p53 tumor suppressor pathways in
tandem, while simultaneously activating oncogenic
Wnt signaling.
Ectopic expression of WIF1 in glioblastoma cell lines
revealed a dose-dependent decrease of Wnt pathway
activity. Furthermore, WIF1 expression inhibited cell
proliferation in vitro, reduced anchorage-independent
growth in soft agar, and completely abolished tumori-
genicity in vivo. Interestingly, WIF1 overexpression in
glioblastoma cells induced a senescence-like phenotype
that was dose dependent. These results provide evidence
that WIF1 has tumor suppressing properties.
Downregulation ofWIF1 in 75% of glioblastomas indi-
cates frequent involvement of aberrant Wnt signaling
and, hence, may render glioblastomas sensitive to inhibi-
tors of Wnt signaling, potentially by diverting the tumor
cells into a senescence-like state.
Keywords: epigenetic silencing, glioblastoma,
senescence, tumor suppressor gene, WIF1, Wnt
pathway.
Glioblastoma is the most malignant primary braintumor with a median survival of only 15 monthsdespite modern therapy comprising surgical
resection followed by combined radiochemotherapy.1
Thus new avenues need to be explored.
High-throughput genomic data derived from human
glioblastomas are readily available for analyses aiming
at uncovering hitherto unrecognized disease mechanisms
suitable as drugable targets, or identifying biomarkers
for response to therapy. However, extracting relevant
and reliable information from such data is not trivial.2
Target gene identification in tumor tissue is often
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complicated by (1) broad genomic copy number aberra-
tions (CNAs), (2) multiple mechanisms of activating and
inactivating genetic and epigenetic alterations, and (3)
the complexity of pathway regulation. Further, the
measurements may be confounded by contaminating
nontumoral cells or the molecular heterogeneity of the
tumor. Thus hidden tumor characteristics may only be
unveiled with a multidimensional approach.3,4
Here we aimed at identifying and validating function-
ally new candidate genes relevant for the malignant be-
havior of glioblastoma. Since gene expression reflects
both gene dosage effects by genomic CNAs and epige-
netic modulation, we interrogated gene expression pro-
files derived from glioblastomas of patients treated
within clinical trials5–7 to infer underlying molecular
changes. In the present study we focused on the chromo-
somal region on chromosome 12 (12q13 to 12q15)
flanked by MDM2 and CDK4 that are known to be
co-amplified in approximately 10% of glioblastomas,
while the region in between is generally not amplified,8
hence potentially indicating the presence of a tumor sup-
pressor gene.
Indeed, by combining gene expression data with data
from genomic copy number analysis, we identified Wnt
inhibitory factor 1 (WIF1) as a new candidate tumor
suppressor gene involved in glioblastoma. This gene
encodes a secreted Wnt antagonist sequestering secreted
Wnt proteins9,10 and is thus predestined as a candidate
tumor suppressor. The interaction of WIF1 with Wnt
ligands blocks their binding with the cell surface
cognate receptor downregulating activation of the
pathway. Hence, loss of WIF1 expression is expected
to aberrantly activate Wnt signaling, which is associated
with cancer. CpG island hypermethylation of the WIF1
promoter as silencing mechanism has been described in
several epithelial cancers11,12 and more recently also in
glioma where it seems to be associated with tumor
grade.13
Here we are reporting the tumor suppressing proper-
ties of WIF1 in in vitro and in vivo models of glioblas-
toma and propose a mechanism of action.
Materials and Methods
Glioblastoma Tissues
Glioblastoma tissues were collected for translational
research with informed consent of the patients. The pro-
tocols were approved by the local ethics committees.
Prediction of Genomic Copy Number Amplifications in
Glioblastoma by a Hidden Markov Model
The glioblastoma micro-array gene expression data
obtained in our laboratory on Affymetrix HG-133
Plus2.0 GeneChips (Gene Expression Omnibus
database at http://www.ncbi.nlm.nih.gov/geo/, acces-
sion number GSE7696)5 were used for amplification
prediction. Probe sets were filtered to exclude those
with low variance, suggestive of no or constant
expression of the gene. For each gene with multiple
probe sets, only the one with the highest variance was
retained. Input to a hidden Markov model (HMM) as
observed sequences were genewise-mean-centered, the
log-scale robust multi-array average normalized
expression data ordered by their positions on a chro-
mosome (http://genome.ucsc.edu/; 2004 freeze) and
discretized into 8 levels of expression intensity. The
HMM had 2 hidden states: The “normal” state
modeled the typical distribution, while the “activated”
state modeled a distribution typical for highly amplified
regions, which is shifted toward higher values. It gener-
ated for each sample and chromosome a matrix of pos-
terior state probabilities at each of the measured loci.
HMM Training
The emission probabilities of the HMM were based on
frequencies of the discrete levels of expression as esti-
mated from gene expression data for all genes from a
large breast cancer sample population profiled with
Affymetrix U133A chips (“normal” state) respectively
from data subsets for genes in regions around the
ERBB2 gene that by statistical examination of the gene
expression data were considered amplified (“activated”
state). A dozen of these calls were tested by reverse tran-
scription PCR and the status of all those tested was con-
firmed. High posterior probabilities for the activated
state are obtained for probe sets in regions where ampli-
fications or another cause results in higher average
expression of contiguous genes. In breast cancer and in
glioblastoma, the method identified primarily activated
regions known from the literature to be subjected to
high degree amplifications (unpublished observation).
Transition probabilities were estimated so that a
posterior probability of 0.5 was a useful cutoff to
identify amplified regions. Posterior state probabilities
were computed using the Markov Modeling Tool
(MAMOT) program14 with a manually curated model
parameter file.
DNA Isolation, Methylation-Specific PCR
Genomic DNA was isolated from paraffin-embedded or
fresh frozen tissue and subjected to bisulfite treatment
using the EZ DNA Methylation Kit (Zymo Research)
followed by nested methylation-specific PCR (MSP), as
described previously.15 During the bisulfite treatment,
unmethylated cytosine, but not its methylated counter-
part, is converted into uracil. MSP for WIF1 was per-
formed via a nested approach using published primer
sequences.12 Peripheral blood lymphocytes and the
colon cancer cell line SW48 were employed as the
WIF1 methylation negative and positive controls,
respectively.
RNA Isolation and Reverse Transcription PCR
Total RNA was extracted using the RNeasy total RNA
extraction kit (Qiagen), and cDNA was synthesized
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using Superscript RT II (Invitrogen). PCR was per-
formed with gene-specific primers for WIF1.12
POLR2A expression was assayed to control for
mRNA integrity using published primers.16 Real-time
quantitative PCR was performed with Fast SybR Green
Master Mix (Applied Biosystem) using the Rotor Gene
6000 Real-Time PCR system (Corbett Life Science).
PCR reactions were run as triplicates. The temperature
profile was as follows: 958C (100 s) followed by 40
cycles at 958C (3 s) to 608C (20 s). The quality of the
products was controlled by the melting curve. Transcript
levels were normalized against human GAPDH.17
WIF1 primers: Forward: 5′-AAGGTTGGCATGGAAG
ACAC-3′; Reverse: 5′- TTAAGTGAAGGCGTGTGCTG
-3′. AXIN2 primers.18
Glioblastoma Cell Lines
Glioblastoma cell lines LN18, LN229, LN235, LN319,
LN401, LN992 were established in our lab, and
U87MG was obtained from the American Type
Culture Collection (ATCC). All glioma cell lines have
been characterized for a defined set of molecular aberra-
tions in our lab, as published previously,19 and were con-
trolled by DNA fingerprinting as described.20 The non–
small cell lung carcinoma cell line A549 and the colon
carcinoma cell line SW48 were obtained from ATCC.
All lines were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen), supplemented with 5% fetal calf
serum (Hyclone) and 100 units/mL penicillin,
100 units/mL streptomycin (Invitrogen). For global
demethylation of DNA, glioblastoma cell lines were
treated with 5 mM 5-aza-2′-deoxycytidine
(Sigma-Aldrich Chemie) for 96 h, with 24-h medium
renewal.21
Plasmids and Small Interference RNAs
The Wnt/b-catenin activity luciferase reporter vectors
TOP5 and FOP5 comprise T-cell factor (TCF)/
b-catenin responsive elements that express synthetic
firefly luciferase from a PGL4.10 backbone with a
minimal TATA box with 5 concatenated TCF binding
sites and 5 mutated binding sites, respectively (a gener-
ous gift of Dr M. van de Wetering).22 The pRL CMV
Renilla luciferase (Promega AG) plasmid was used to
normalize for transfection efficiency. The WIF1
expression vector and its empty control pcDNA3.1
vector were generous gifts from Professor Qian Tao,
Cancer Center, Chinese University of Hong Kong.23
To generate the stably transfected clones in the LN229
cell line, WIF1 was subcloned into the vector
pIRES2-EGFP (Clontec). WIF1 knockdown was
achieved using small interference RNAs (siRNAs;
ON-TARGET plus SMART pool, Dharmacon RNA
Technologies) targeting 3 domains of the WIF1
RNA, and the control experiments were performed
with the corresponding ON-TARGET plus nontargeting
pool.
Transfection and Dual Luciferase Assay
For transient transfections, cells were grown to 80%
confluence in 24-well plates. Transfections were per-
formed with Lipofectamine 2000 transfection reagent
(Invitrogen), and siRNAs were transfected with
INTERFERin (Polyplus-Transfection SA) reagent as
suggested by the manufacturers.
For Wnt pathway activity reporter assays, cells were
transfected with 0.25 mg of either of TOP5 or FOP5
and 5 ng of Renilla pRL CMV luciferase construct,
and incubated at 378C for 28 h. Subsequently the
firefly and Renilla luciferase activities were measured
using Dual-Luciferase Reporter assay reagents
(Promega). The Renilla luciferase activity was used to
normalize for transfection efficiency. The Wnt
pathway-specific activity status was determined by the
TOP5/FOP5 ratio. A TOP5/FOP5 ratio significantly
higher than 1 was considered as an active Wnt
pathway. The cell line A549 served as positive
control.24 These experiments were performed in tripli-
cate and were replicated 2 or 3 times independently.
Modulation of the Wnt pathway in established cell
lines was effectuated by cotransfection of corresponding
plasmids or siRNAs. In these experiments, Wnt pathway
activation status was assessed 72 h post transfection. For
stable transfections, cells were transfected either with
theWIF1 expression vector or a control vector followed
by selection with G418. Resistant clones were selected
and maintained in 400 mg/mL of G418.
Crystal Violet Assay
For growth curves, 1 × 104 cells were seeded in 24-well
plates. At every time point, culture medium was
removed, cells were washed with 1 mL of 1.0× phos-
phate buffered saline (PBS), and 300 mL of crystal
violet solution was added per well. After 10 min at
378C, crystal violet solution was removed and plates
were washed with 1× PBS. Plates were left to dry over-
night, and 500 mL of 1% sodium dodecyl sulfate in dis-
tilled water was added per well. Absorbance was then
measured at 595 nm using a plate reader.
Enzyme-Linked Immunosorbent Assay
The cell supernatant, collected after 2 days of culture,
was quantified for secreted WIF1 with a sandwich
enzyme-linked immunosorbent assay (R&D System) fol-
lowing the manufacturer’s instructions. Data were nor-
malized to the cell number. For control experiments of
small interfering WIF1 efficiency, the medium was col-
lected after 3 days of culture, and data were normalized
to protein content.
Colony Formation Assay in Soft Agar
Growth in soft agar was determined in 6-well plates con-
taining 2 mL of 1% agar in complete medium as the
bottom layer, and 1 mL of 0.4% agar in complete
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medium as the top layer. Cells, 1 × 104 and 2 × 103,
respectively, were seeded in triplicate. Cultures were
maintained under standard conditions, and after 3
weeks the number of colonies was determined with an
inverted phase-contrast microscope, where a group of
.50 cells was scored as colony.
Nude Mouse Tumorigenicity Assay
Cells (7 × 106) were resuspended in Dulbecco’s modified
Eagle’s medium and subcutaneously injected into the
flanks of 6- to 9-week-old female Swiss nu/nu mice.
Five mice per group were injected, and tumor size was
measured weekly with a caliper. Tumor volume (mm3)
was calculated as (length × width2)/2. The protocol
was authorized by the local veterinary authorities
(VD1181-3).
Flow Cytometry Measurement of Cell Morphology
Cells were grown until confluence detached using a sol-
ution of 2 mM ethylenediaminetetraacetic acid in PBS
and resuspended in PBS. Cell size was evaluated by
forward scatter (FS) and side scatter (SS) analysis using
a Beckman Coulter FC500 5-color analyzer. More
than 1 × 104 events were counted for all samples.
Thresholds for FS and SS were arbitrarily defined.
Histochemistry
Cells were seeded onto glass coverslips coated with
poly-L-lysine and cultured until confluence. Cells were
stained for the activity of SA-b-galactosidase using the
b-Galactosidase Staining Kit (Biovision), following the
manufacturer’s instructions, and counterstained with
4′,6-diamidino-2-phenylindole (DAPI). SA-b-galactosi-
dase activity and nuclear morphology were visualized
by bright field and fluorescence microscopy (Leica
Leitz DMRB). Cells were scored in 10 randomly
taken fields.
Results
Gene Expression–Based Prediction
Gene expression profiles obtained in our lab from 80
human glioblastoma samples5 were used to infer under-
lying molecular alterations. Inspection of the chromoso-
mal region encompassing CDK4 and MDM2 using an
HMM predicted separate amplifications of these proto-
oncogenes (Fig. 1A), that is, no co-amplification com-
prising the genomic region in between. Although this
2-state HMM was not constructed to detect deleted
loci, we had indications of several loci with very low
average and low maximum posterior probability for
the activated state, thus pointing to loci potentially tar-
geted for expression silencing. The array comparative
genomic hybridization (aCGH) data of this cohort
(Shay and Lambiv, manuscript in preparation)
confirmed the amplifications and indicated deleted loci
at positions of low amplification probability (Fig. 1B).
The deleted locus in proximity to CDK4 was queried
by a single Bacterial Artificial Chromosome (BAC)
probe (RP11-97A6) in the aCGH data and was scored
as deleted in 16 of 55 glioblastomas (29%). The
minimal deleted locus in proximity to MDM2 affected
2 BACs (RP11-109L8 and RP11-18B8), spanning
approximately 1.5 Mb and encompassing 6 known
genes (WIF1, LEMD3, MSRB3, HMGA2, IRAK3,
and HELB) (http://genome.ucsc.edu/; 2004 freeze,
hg17). Deletion of this locus affected 7 of 69 (10%) glio-
blastomas. Of note, most samples with co-amplification
of MDM2 and CDK4 exhibited a deletion of the
genomic region between these 2 loci, suggesting a
merged amplicon (Fig. 1C). Hence, this interesting
pathogenetic constellation combines amplification of 2
oncogenes plus deletion of putative tumor suppressor
genes in a single event. This CNA pattern was confirmed
in the database of The Cancer Genome Atlas (TCGA)25
(Supplementary Fig. S1). Among the potential candidate
target genes, WIF1 showed the largest mRNA
expression variation in this data set, and median WIF1
expression was significantly lower in glioblastoma than
in 4 nonneoplastic brain tissues (P ¼ .001, 2-sample
Wilcoxon test) (Fig. 1D). The other genes exerted
expression levels similar to those of normal brain
tissue and/or showed relatively low variation in our
data set. The low expression of WIF1 in glioblastoma
was confirmed in all 5 independent glioblastoma data
sets analyzed26–30 (Fig. 1E). Furthermore, decreasing
expression of WIF1 is associated with tumor grade in
astrocytoma, as suggested by 2 independent data
sets.31,32WIF1 encodes a soluble Wnt pathway antagon-
ist sequestering Wnt proteins, thereby inhibiting their
function.9 Since Wnt signaling is proto-oncogenic,33
modulators/antagonists of Wnt signaling are good can-
didates for tumor suppressor functions.34
WIF1 is Silenced Both by Genomic Deletion and
Promoter Hypermethylation
While expression data suggested lowWIF1 expression in
76% of glioblastomas of our gene expression data set,
corresponding analysis of the aCGH data showed hemi-
zygous deletions at theWIF1 locus in only 10% (7/69),
suggesting other mechanisms of silencing. Subsequent
analysis of the WIF1 promoter by MSP revealed hyper-
methylation in 2 of 6 glioblastomas with hemizygous
deletion, satisfying the 2-hit model of tumor suppres-
sors. In an extended series of 110 glioblastomas, 26%
exerted a methylated WIF1 promoter (Fig. 2). WIF1
mutations have not been reported from glioblastoma
(0/444), according to the Catalogue of Somatic
Mutations in Cancer (COSMIC) database.35
Interestingly, a significant association with methyl-
ation of the O6-methylguanine DNA-methyltransferase
(MGMT) promoter was observed (P ¼ .004, 2-sided
Fisher exact test). MGMT methylation is a known pre-
dictive factor for response to alkylating agent therapy
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in glioblastoma.15,36 The MGMT methylation status
was available for 107 cases from previous studies, of
which 56 were MGMT methylated (52%).5,37–40 Most
established glioblastoma cell lines (14 of 15) showed
hypermethylation of the WIF1 promoter. Only LN992
exhibited an unmethylated WIF1 promoter. Treatment
Fig. 1. Gene expression–based prediction of copy number aberrations (CNAs) in glioblastoma. (A) The maximum (red) and mean (blue)
amplification probabilities on chromosome 12q14–12q15 were estimated from glioblastoma gene expression data by a hidden Markov
model (HMM). The interrogated region flanked by CDK4 and MDM2 encompasses a !11 Mb window. (B) The respective mean DNA
copy number of this chromosomal region was determined by array comparative genomic hybridization (aCGH, Humarray 3.0 and 3.1 of
the University of California at San Francisco; manuscript in preparation). The bacterial artificial chromosome (BAC) probes are ordered by
their genomic positions. The BACs corresponding to CDK4 and MDM2 BACs are shown in red. (C) The heat map visualizes the structure
of the aCGH data shown in (B) for the genomic region encompassing 12q13 to 12q15 from 68 glioblastomas. The BACs are ordered by
their genomic position, while the glioblastomas on the x-axis are ordered by similarity using Sorting Points into Neighborhood
software.57 Blue depicts deletion; red, amplification; and white, missing data. The color scale is truncated to [21, 1] for presentation.
The BAC corresponding to CDK4 is GS-561N1; for MDM2, CTB-136O14 (red); and for WIF1, RP11-18B8 (blue). (D) WIF1 expression
(Affymetrix probe set 204712_at) in glioblastoma is significantly lower than in nonneoplastic brain tissues (P ¼ .001), as determined in
our gene expression data set.5 (E) Low WIF1 expression was confirmed in 5 independent glioblastoma data sets (Freije et al., red; Rich
et al., violet; Phillips et al., orange; Sun et al., dark blue; Horvath et al., green; our data set, Murat et al., light blue).26–30 WIF1
expression values are median centered within each data set independently.
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of glioblastoma cell lines with the DNA demethylating
agent 5-aza-cytidine for 96 h restored WIF1 expression
(Fig. 3A).
Modulation of WIF1 Expression Affects Wnt Pathway
Activation
Wnt pathway activity was tested in a set of 7 glioblas-
toma cell lines using the TOP5/FOP5 Wnt signaling
reporter system that investigates transactivation of the
TCF responsive element (5 concatenated TCF binding
sites) normalized to transactivation of the corresponding
mutated binding sites (5 concatenated mutated TCF
binding sites). Wnt pathway activity was present in all
cell lines with low or no detectable WIF1 expression,
while LN235 and LN992 showed no significant Wnt
activity (TOP5/FOP5 ≤ 1), in accordance with high
levels of endogenous WIF1 expression (Fig. 3A and B).
Given the role of WIF1 in regulation of Wnt signaling,
and the prevalence of low WIF1 expression in glioblas-
toma, we first investigated the glioblastoma cell lines
with endogenous Wnt pathway activity and asked if
WIF1 overexpression translates into impaired Wnt sig-
naling. Indeed, forced expression of WIF1 inhibited
Wnt activity in a dose-dependent manner (Fig. 3C).
Next we examined whether in the 2 cell lines with
endogenous WIF1 expression and no Wnt signaling
activity (LN992 and LN235, Fig. 3A and B) the
pathway could be activated upon WIF1 silencing.
Using siRNA to knock down WIF1 expression, we
detected induction of Wnt signaling activity in both
cell lines, in contrast to the controls with nontargeting
siRNAs (Fig. 3D, Supplementary Fig. S2).
Fig. 2. Promoter methylation of WIF1 in glioblastoma.
Methylation-specific PCR (MSP) for WIF1 was performed via a
nested approach using published primer sequences.12 DNA
isolated from peripheral blood lymphocytes (PBLs) and the colon
cancer cell line SW48 served as controls for unmethylated (U)
and methylated (M) WIF1 promoter status, respectively.
Glioblastomas #2445, #2447, and #2448 contain a methylated
WIF1 promoter, whereas the others harbor only an unmethylated
gene promoter.
Fig. 3. Alteration of WIF1 expression modulates Wnt signaling. (A) Glioblastoma cell lines were treated with the DNA demethylating agent
5-aza-cytidine for 4 days. All 3 WIF1 nonexpressing cell lines with a methylated WIF1 promoter re-expressed WIF1 mRNA in response to
5-aza-cytidine treatment (LN319, LN401, U87). Only LN992 was completely unmethylated. The lower panel shows mRNA expression of the
POLR2A gene used to control for mRNA quality. The methylation status of the cell lines displayed was determined by MSP. (B) Wnt signaling
activity was measured with the TCF luciferase reporter (TOP5/FOP5; ratio .1 Wnt pathway active). The non–small cell lung carcinoma cell
line A549 served as positive control. LN235 and LN992 show no significant activity. (C) Wnt signaling (TOP5/FOP5) after cotransfection of
increasing amounts (0 mg, 0.5 mg, and 1 mg) of the WIF1 expression vector into glioblastoma cell lines U87, LN319, LN401, and A549. The
DNA quantity was adjusted with the control vector. (D). LN235 and LN992, negative for Wnt signaling activity, were transfected with
siWIF1 and the siScrambled as control. Knockdown of WIF1 induced Wnt pathway activity (TOP5/FOP5) in both LN992 and LN235.
WIF1 expression measured after transfection of siWIF1 or the respective control siRNAs is documented in Supplementary Fig. S2. Results
are marked with 1 asterisk (*) if P, .05 and 2 (**) if P, .01.
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WIF1 Expression Decreases Anchorage-Dependent and
Anchorage-Independent Growth
We further investigated the biological effects of WIF1 in
the glioblastoma cell lines LN319 and U87. Stably trans-
fected cell clones were characterized for WIF1
expression and WIF1 secretion and their effect on cell
growth (Fig. 4A and B). WIF1 overexpressing LN319
cells showed reduced Wnt pathway activity (P, .005)
compared with the respective control cells (Fig. 4C).
The downregulation of the canonical pathway was also
confirmed by measuring the expression of AXIN2, a
prototypic Wnt target gene41 (Fig. 4D). The specificity
of the observed effect on the Wnt pathway was deter-
mined by silencing of WIF1 by siRNAs. WIF1 knock-
down indeed rescued transactivation of the TCF
reporter in the ectopically expressing WIF1 LN319
cells, confirming that the detected attenuation of the
Wnt pathway was indeed WIF1 dependent (Fig. 4E
and F). Glioblastoma cell lines LN229 and U87 were
analyzed accordingly. While experiments in LN229 con-
firmed these results (Supplementary Fig. S3), U87 cells
became invariably resistant to ectopic WIF1 expression
over time (passages 20 to 25), although initially sensitive
(Fig. 3C). In some cases, clones had lost or attenuated
WIF1 expression/secretion, regardless of continued
selection with G418 (Supplementary Fig. S4A).
However, most clones gained Wnt pathway activity
despite WIF1 expression and WIF1 secretion.
Furthermore, cells were no longer sensitive to knock-
down of WIF1 expression, reflected in no notable
increase of pathway activity (Supplementary Fig. S4B
and C).
TheWIF1-expressing cell clones were utilized to inves-
tigate the effect of WIF1-mediated downregulation of the
Wnt pathway on proliferation. Anchorage-dependent
Fig. 4. LN319 cell clones stably transfected with WIF1 show reduced Wnt pathway signaling. Two stably transfected LN319 clones were
analyzed for WIF1 expression by qRT-PCR (normalized to the control cells transfected with the empty vector, pcDNA3.1) (A) and WIF1
secretion by enzyme-linked immunosorbent assay (ELISA) (B). Wnt pathway signaling was measured both with the TCF luciferase
reporter (TOP5/FOP5) and normalized to the control cells (C) and by measuring AXIN2 mRNA expression (D). The specificity of the
WIF1-induced effects in the 2 clones was controlled by transfection of specific siRNAs against WIF1 or a respective scrambled control.
Wnt pathway signaling was measured using the TCF reporter (E) and WIF1 secretion using ELISA (F). Results are marked with 1 asterisk
(*) if P, .05 and 2 (**) if P, .01.
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proliferation measured over 3 days was significantly
decreased (P, .005) in WIF1-overexpressing LN319
clones (Fig. 5A). Even more striking results were obtained
investigating the effects on anchorage-independent cell
growth. The ability to form colonies in soft agar after 3
weeks of culture was indeed greatly reduced upon
WIF1 overexpression (Fig. 5B and C). During
the soft agar experiment, we observed that
WIF1-overexpressing clones were initially able to pro-
liferate, forming very small clusters of cells, but then
stopped dividing after a few days, potentially in
response to increasing concentrations of secreted
WIF1. In accordance, the colony formation potential
was reduced in a WIF1 dose-dependent manner. The
high expressing WIF1 clone LN319-WIF1_C2 dis-
played 90% fewer colonies, while in the intermediate
clone LN319-WIF1_C6, the colony number was
reduced by 63%. Similar results were obtained in
LN229 (Supplementary Fig. S3A–E). In contrast, the
corresponding experiments in WIF1 stably transduced
U87 clones showed initially reduced growth potential
that was lost at later passage (passage 4 vs passages 20
to 25) (Supplementary Fig. S4D and E), in line with the
observed gain of resistance toWIF1 expression, as detailed
above (Supplementary Fig. S4B and C).
WIF1 Suppresses Tumorigenicity in a Xenograft Mouse
Model
Ectopic expression of WIF1 in LN319 cells completely
suppressed the inherent tumorigenicity of this glioblas-
toma cell line. While mice injected with control cells
started to develop tumors 25 days after injection, no
tumors were detectable in the mice injected with
WIF1-expressing cell clones over the observation
period of 100 days (Fig. 5D). In contrast, the 2 tested
WIF1-transduced U87 clones retained tumorigenicity
similar to the vector control, in line with development
of resistance to WIF1 in vitro. Altogether, these exper-
iments suggest an important role of the Wnt pathway
in the development of glioblastoma and a tumor sup-
pressing function for WIF1.
WIF1 Overexpression Promotes a Senescence-like
Proliferation Arrest
Observation of WIF1-overexpressing cells (LN319 and
LN229) until confluence revealed a striking change in
morphology. While control cells started to grow on
top of each other without apparent contact inhibition,
the WIF1-expressing cells displayed a phenotype
Fig. 5. WIF1 overexpression reduces the growth potential of LN319 cells in vitro and in vivo. Growth ofWIF1-transduced LN319 clones and
the respective empty vector control (pcDNA3.1) was followed over 3 days in culture (A). Anchorage-independent growth was evaluated in
soft agar; representative images are shown (B). The average number of colonies counted in 10 randomly chosen fields is reported (C). Tumor
growth kinetics of nude mouse xenografts, after subcutaneous injection of WIF1-overexpressing clones and the corresponding empty vector
control cells are displayed. The WIF1-overexpressing clones did not form any measurable tumors. The average tumor volume per group (5
mice) is reported (D). Results are marked with 1 asterisk (*) if P, .05 and 2 (**) if P, .01.
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reminiscent of senescent cells with increased cell size.
Next we evaluated recognized markers for senescence,
including enhanced granularity of the cytoplasm,
appearance of multinucleated cells, and presence of
senescence-associated b-galactosidase activity.42,43
Quantification of morphological changes was performed
using fluorescence-activated cell sorting analysis.
Senescence-like cells were defined as: highly granulated
cells ¼ high SS; big cells ¼ high FS. We detected an
increased percentage of senescence-like cells in
WIF1-transfected clones with a positive relationship to
WIF1 secretion of the respective clones (Fig. 6A and B,
Supplementary Fig. S3F and G). Similar differences
were observed upon double staining of the cells with
Fig. 6. WIF1 expression and detection of senescence-like cells. Cell morphology of the different LN319 clones was analyzed by
fluorescence-activated cell sorting (FACS) (A). Senescence-like cells were defined as highly granulated cells, high side scatter (SS) (blue
rectangle), and big cells, high forward scatter (FS) (red rectangle). (B) Quantification of FACS analysis, % of highly granulated cells (SS
high, blue), and % of both highly granulated and big cells (FS and SS high, red). Quantification of LN319 (C) and LN229 (E) cells
positive for SA-b-galactosidase activity scored in 10 different randomly chosen fields. (D, F) Representative images of clones stained for
SA-b-galactosidase and DAPI are shown (200×). Large, SA-b-galactosidase positive (blue) and multinucleated cells are highlighted with
red arrows. Results are marked with 1 asterisk (*) if P, .05 and 2 (**) if P, .01.
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SA-b-galactosidase and DAPI, which visualizes nuclear
morphology. In the LN319- and LN229-derived
WIF1-overexpressing clones, we scored an increased
population of both multinucleated and SA-b-galactosidase
positive cells (Fig. 6C–F).
Discussion
Little is known about the role of the Wnt pathway in the
malignant behavior of human glioblastoma. Using a
combined genomics approach, we provided evidence
that the Wnt antagonist WIF1 is targeted for silencing
in glioblastoma, hence represents a good candidate
tumor suppressor. In most glioblastomas, WIF1 silen-
cing is mediated by genomic deletion, promoter hyper-
methylation, or both. A recent study supports a role
for a deregulated Wnt pathway in malignant glioma,
showing that additional Wnt pathway inhibitors are epi-
genetically inactivated, including the family of secreted
frizzled-related proteins, dickkopf, and naked.44 In con-
trast, mutations in b-catenin (CTNNB1) and APC are
rare in glioblastoma (1/180 and 1/152; https://cma.
nci.nih.gov/cma-tcga/geneView/index).25
Here we demonstrated that forced WIF1 expression
significantly reduced Wnt signaling in glioblastoma cell
lines, while knockdown of WIF1 induced the pathway.
This effect was paralleled by a WIF1 dose-dependent
attenuation of cell proliferation in vitro, particularly
striking for anchorage-independent growth, and associ-
ated with complete abrogation of tumorigenicity.
However, the highly malignant glioblastoma cell line
U87, although initially sensitive, escaped the effect by
either suppressing ectopic expression of WIF1 or by
becoming functionally resistant to WIF1 expression
over time, restoring activation of the Wnt pathway. In
ephitelial and mesenchymal tumors, a tumor suppres-
sing role forWIF1 has been proposed. In gastrointestinal
cancer cell lines, restoration of WIF1 expression was
shown to reduce growth in vitro,11 and in cell lines
from human renal cell carcinoma, prostate cancer, and
osteosarcoma WIF1 overexpression has been reported
to inhibit tumor growth in vivo.45–47
Here, we propose a mechanism by which WIF1
overexpression may exert the growth-inhibiting
effect. The WIF1-dependent emergence of enlarged,
flattened cells associated with increased detection
of SA-b-galactosidase positive, multinucleated cells
suggests that WIF1 overexpression induces a senescence-
like phenotype in glioblastoma cells. Wnt signaling is
involved in diverse processes, from early embryonic pat-
terning34 to regulation of stem cell self-renewal and
differentiation.48,49 Consequently, Wnt pathway dysre-
gulation can dramatically alter differentiation and cell
fate decisions.50 Recently, Ye et al.51 reported that
downregulation of canonical Wnt signaling was directly
associated with the onset of cell senescence in primary
human cells. Indeed, in human primary fibroblasts,
the process that leads to the formation of
senescence-associated heterochromatin foci (SAHF), an
early marker of senescence, was initiated upon
activation of GSK3b, a key effector of the repressed
Wnt signaling pathway.52 This Wnt-dependent for-
mation of SAHF is independent of the RB1 and TP53
pathways, 2 tumor suppressor pathways frequently inac-
tivated in glioblastoma. Thus, induction of senescence
via Wnt pathway inhibition may prove a promising
therapeutic strategy.
The CNA patterns reported in this study have a most
interesting feature: Most of the glioblastomas with a del-
etion at the WIF1 locus have concomitant high-level
amplifications of the proto-oncogenes CDK4 and
MDM2 (Fig. 1C), probably organized extrachromoso-
mally in double minutes. This may suggest that the
CNAs of this CHR12q14-15 locus alone, combining
co-amplification of CDK4 and MDM2 with deletion of
the chromosomal region in between, subverts in 1
genetic event 2 important tumor suppressing pathways,
the RB- and TP53-pathway, respectively, while simul-
taneously activating proto-oncogenic Wnt signaling
(Fig. 7). Of note, the RB1 and TP53 tumor suppressor
pathways are themselves important effectors of senes-
cence. This observation was confirmed in the large
TCGA glioblastoma data set (Supplementary Fig. S1)
and underlines the need for concerted targeting of signal-
ing pathways that cooperate in glioblastoma, including
the Wnt pathway. Specific inhibitors for CDK4 and
MDM2 are in clinical development.53 Small molecule
inhibitors targeting the Wnt pathway by novel mechan-
isms have been proposed recently. They comprise inhibi-
tors of Wnt production by targeting Porcn, and
inhibitors of Wnt response that stabilize Axin, promot-
ing the association of b-catenin with the destruction
complex,54,55 or b-catenin interaction disruptors
Fig. 7. Model for mechanisms implicated in deregulation of both
tumor suppressing and proto-oncogenic pathways on
chromosome 12. The model suggests that deletion at the WIF1
locus, if concomitant with amplification of the proto-oncongenes
CDK4 and MDM2, can subvert the important tumor suppressing
pathways regulated by RB1 and TP53 while simultaneously
activating proto-oncogenic Wnt signaling.
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preventing b-catenin from associating with TCF or
cAMP response element binding. The observation of fre-
quent inactivation of genes coding for secreted Wnt
antagonists in glioma may favor the use of inhibitors
of Wnt production or the development of molecules
sequestering Wnt family members. Such intervention
may have the additional advantage of interfering with
tumor angiogenesis, since the ligands Wnt7a/7b have
been shown to be involved in brain angiogenesis and
induction of the blood-brain barrier, both relevant
factors for glioma vascularization and therapy.56
The present study provides the rationale for investi-
gating inhibitors of Wnt signaling in glioblastoma as a
new avenue for individualized therapy. The addition of
a Wnt pathway inhibitor to the current standard of care
of combined radiochemotherapy with the alkylating
agent temozolomide may improve outcomes particularly
in patients whose tumors carry a methylatedMGMT pro-
moter,15 due to the significant association with WIF1
methylation. However, the importance of the Wnt
pathway that is interlinked with other mitogenic path-
ways may rapidly select for resistance in a corresponding
single-agent therapy, as suggested by the experiments
with the highly malignant glioblastoma cell line U87.
Supplementary Material
Supplementary material is available online at Neuro-
Oncology (http://neuro-oncology.oxfordjournals.org/).
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